



Contacts: Meg McGilley
Chief Financial Officer
(858) 509-3670

Rob Whetstone
PondelWilkinson, Inc.
(310) 279-5963

**SOMAXON PHARMACEUTICALS TO REPORT 2006 FIRST QUARTER
FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MAY 10, 2006**

SAN DIEGO, CA – May 3, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2006 first quarter financial results after the market closes on Wednesday, May 10, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. EDT (1:30 p.m. PDT) to review the financial results and answer questions.

The conference call will be available to interested parties through live audio Internet broadcast at www.somaxon.com and www.opencompany.info. The call will also be archived and accessible at both sites for approximately 14 days. Alternatively, callers may participate in the conference call by dialing (800) 257-1927 (domestic) or (303) 262-2051 (international). A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international), and entering pass code: 11060307.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for the treatment of pathological gambling and in a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company's web site at www.somaxon.com.

###